These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26410247)

  • 21. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.
    Mol PG; Straus SM; Piening S; de Vries JT; de Graeff PA; Haaijer-Ruskamp FM
    Drug Saf; 2010 Jun; 33(6):463-74. PubMed ID: 20486729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
    Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health care provider knowledge of drug formulary status in ambulatory care settings.
    Shih YC; Sleath BL
    Am J Health Syst Pharm; 2004 Dec; 61(24):2657-63. PubMed ID: 15646700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postmarket safety of drugs approved by Health Canada on the basis of clinical and surrogate outcomes: a cohort study.
    Lexchin J; Ahmed T
    CMAJ Open; 2015; 3(3):E286-91. PubMed ID: 26442227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Need for an improved submission process for listing drugs for reimbursement in Canadian provinces.
    West R; Borden EK; Collet JP; Rawson NS; Tonks RS
    Can J Clin Pharmacol; 2003; 10(4):207-10. PubMed ID: 14712327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New drug approval times and safety warnings in the United States and Canada, 1992-2011.
    Rawson NS
    J Popul Ther Clin Pharmacol; 2013; 20(2):e67-81. PubMed ID: 23650206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Documentation of pediatric drug safety in manufacturers' product monographs: a cross-sectional evaluation of the canadian compendium of pharmaceuticals and specialities.
    Uppal NK; Dupuis LL; Parshuram CS
    Paediatr Drugs; 2008; 10(3):193-7. PubMed ID: 18454571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medicine reimbursement recommendations in Canada, Australia, and Scotland.
    Lexchin J; Mintzes B
    Am J Manag Care; 2008 Sep; 14(9):581-8. PubMed ID: 18778173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delisting of drugs in Ontario. How attitudes and prescribing strategies of family physicians in the Kingston area changed.
    Godwin M; Chapman J; Mowat D; Racz W; McBride J; Tang J
    Can Fam Physician; 1996 Jul; 42():1309-16. PubMed ID: 8754700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study.
    Lexchin J
    Healthc Policy; 2016 Nov; 12(2):65-75. PubMed ID: 28032825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of health-related quality of life information in managed care formulary decision-making.
    Wu WK; Sause RB; Zacker C
    Res Social Adm Pharm; 2005 Dec; 1(4):579-98. PubMed ID: 17138497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of federal warnings on publically funded desmopressin utilization among children in Ontario.
    Gomes T; Juurlink DN; Moore I; Maguire JL; Mamdani MM
    J Pediatr Urol; 2012 Jun; 8(3):249-53. PubMed ID: 21767992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors that influence patient response to requests to change to a unified restrictive formulary.
    Smetana GW; Davis RB; Phillips RS
    J Gen Intern Med; 2004 Dec; 19(12):1212-9. PubMed ID: 15610332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence-based and value-based formulary guidelines.
    Neumann PJ
    Health Aff (Millwood); 2004; 23(1):124-34. PubMed ID: 15002635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Formulary decisions: then and now.
    Boucher BA
    Pharmacotherapy; 2010 Jun; 30(6 Pt 2):35S-41S. PubMed ID: 20500042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory post-market drug safety advisories on cardiac harm: A comparison of four national regulatory agencies.
    Hooimeyer A; Bhasale A; Perry L; Fabbri A; Mohammad A; McEwin E; Mintzes B
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00680. PubMed ID: 33169534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database.
    Levy AR; O'Brien BJ; Sellors C; Grootendorst P; Willison D
    Can J Clin Pharmacol; 2003; 10(2):67-71. PubMed ID: 12879144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.